Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vitro Biopharma's share price is $0.00.
Vitro Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2022 was $0.03. Hence, Vitro Biopharma's PS Ratio for today is 0.00.
Good Sign:
Vitro Diagnostics Inc stock PS Ratio (=2.44) is close to 10-year low of 2.44
The historical rank and industry rank for Vitro Biopharma's PS Ratio or its related term are showing as below:
VTRO'
s PS Ratio Range Over the Past 10 Years
Min: 3.08 Med: 17.69 Max: 115
Current: 2.44
During the past 13 years, Vitro Biopharma's highest PS Ratio was 115.00. The lowest was 3.08. And the median was 17.69.
VTRO's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.655
vs VTRO: 2.44
During the past 12 months, the average Revenue per Share Growth Rate of Vitro Biopharma was 153.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 218.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 132.70% per year.
During the past 13 years, Vitro Biopharma's highest 3-Year average Revenue per Share Growth Rate was 218.80% per year. The lowest was 26.00% per year. And the median was 88.95% per year.
Back to Basics: PS Ratio
Vitro Biopharma (AMEX:VTRO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Vitro Biopharma PS Ratio Related Terms
Vitro Biopharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Vitro Biopharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vitro Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitro Biopharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vitro Biopharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Vitro Biopharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Vitro Biopharma's Share Price of today is $0.00. Vitro Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Vitro Biopharma (VTRO) has a PS Ratio of 0.00 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vitro Biopharma and its competitors. Over the past decade, Vitro Biopharma's PS Ratio has ranged from 3.08 to 115.00.
Is Vitro Biopharma's PS Ratio too high?
Vitro Biopharma's current PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 3.08 to a high of 115.00.
How does Vitro Biopharma's PS Ratio compare to ?
Vitro Biopharma's PS Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.66. Historically, Vitro Biopharma's own PS Ratio has ranged from 3.08 to 115.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vitro Biopharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitro Biopharma's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current PS Ratio of 0.00. The current PS Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current PS Ratio is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTRO has been successfully added to your 
